Two studies investigating MS treatments in pregnancy
Researchers from Teva Pharmaceuticals have published a large case series of 647 glatiramer acetate exposed pregnancies that were reported to the global pharmacovigilance database. More information can be found here.
Clinical researchers affiliated to two neurology departments in Western Australia have published a small case series of 14 pregnancies in 12 MS patients who had been exposed to ocrelizumab within 6 months prior to conception or during pregnancy. More information can be found here.